Skip to main content
SpringerLink
Log in

Data on the use of antivirals to treat cytomegalovirus infection in infants are limited, with ganciclovir being the current first choice

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Pediatr Drugs 2009; 11(5): 309–21

    Article  Google Scholar 

  2. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009 Sep 4; 58(RR-11): 1–166

    PubMed  Google Scholar 

  3. Acosta EP, Brundage RC, King JR, et al. NIAID ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther 2007 Jun; 81(6): 867–72

    Article  PubMed  CAS  Google Scholar 

  4. Kimberlin DW, Acosta EP, Sánchez PJ, et al. on behalf of the NIAID Collaborative Antiviral Study Group. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008 Mar 15; 197(6): 836–45

    Article  PubMed  CAS  Google Scholar 

  5. Henkin CC, Griener JC, Ten Eick AP. Stability of valganciclovir in extemporaneously compounded liquid formulations. Am J Health Syst Pharm 2003 Apr 1; 60(7): 687–90

    PubMed  CAS  Google Scholar 

  6. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994 Aug; 48(2): 199–226

    Article  PubMed  CAS  Google Scholar 

  7. Luck S, Sharland M, Griffiths P, et al. Advances in the antiviral therapy of herpes virus infection in children. Expert Rev Anti Infect Ther 2006 Dec; 4(6): 1005–20

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Data on the use of antivirals to treat cytomegalovirus infection in infants are limited, with ganciclovir being the current first choice. Drugs Ther. Perspect 26, 10–11 (2010). https://doi.org/10.2165/11205270-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11205270-000000000-00000

Search

Navigation